Advanced search
Publication Cover
Journal of Medical Economics Volume 16, 2013 - Issue 4
Submit an article Journal homepage
841
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis

Jennifer H. LoflandJanssen Scientific Affairs, HECOR Horsham, PAUSACorrespondence[email protected] [email protected] [email protected]
,
Peter MallowDepartment of Health Economics, S2 Statistical Solutions Inc. Cincinnati, OHUSA
&
John RizzoDepartment of Economics and Preventive Medicine, Stony Brook University Medical Center Stony Brook, NYUSA
Pages 461-467 | Accepted 05 Feb 2013, Published online: 27 Feb 2013

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Kabirraaj Toor, Eric Druyts, Jeroen P. Jansen & Kristian Thorlund. (2015) Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. Journal of Medical Economics 18:6, pages 437-446.
Read now
Feng Xie. (2015) The economics of adalimumab for ulcerative colitis. Expert Review of Pharmacoeconomics & Outcomes Research 15:3, pages 373-377.
Read now
Hugh J Freeman. (2013) Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Therapeutics and Clinical Risk Management 9, pages 451-456.
Read now

Articles from other publishers (3)

Mattias Neyt, Annick Christiaens, Marina Aloi, Lissy de Ridder, Nicholas M Croft, Sibylle Koletzko, Arie Levine, Dan Turner, Richard K Russell, Frank M Ruemmele & Gigi Veereman. (2021) Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment. JMIR Formative Research 5:1, pages e13888.
Crossref
Abhinav Vasudevan, Peter R Gibson & Daniel R Van Langenberg. (2019) Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 25:9, pages 1462-1473.
Crossref
Bikash Devaraj & Andreas M. Kaiser. (2015) Surgical Management of Ulcerative Colitis in the Era of Biologicals. Inflammatory Bowel Diseases 21:1, pages 208-220.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.